Tiziana Life Sciences Ltd

TLSA

$1.00

$-0.01 (-1.48%)

After Hours

Tiziana Life Sciences chair Gabriele Cerrone buys 42,357 shares at $0.99, lifts stake to 34.93%

Loading chart...

IndexN/A

Market Cap0.06B

Enterprise Value0.01B

Income$-0.01B

Sales$0.00B

EmployeesN/A

P/E-3.16

P/SN/A

P/B1.75

P/C-7.04

EV/EBITDA-0.52

EV/SalesN/A

EPS (ttm)-0.32

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.34M

Shs Outstand0.06B

Change-1.48%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 2511:31AMQualcomm raises long-term targets as analysts highlight data center, edge AI opportunities(proactiveinvestors.com)09:06AMTiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial(proactiveinvestors.com)07:00AMTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial(globenewswire.com)

Jun 1507:00AMTiziana Life Sciences Announces Purchase of Shares by Executive Chairman(globenewswire.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

CERRONE GABRIELE M

Award

15.0K

$1.11

$17K

Jun 12, 26

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

CEO: Ivor R. ElrifiEmployees: 10www.tizianalifesciences.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$15.79M	$17.98M	$14.59M	$27.37M	$28.03M	$7.77M	$7.82M	$8.25M
Operating Income	$-15.79M	$-17.98M	$-14.59M	$-27.37M	$-28.03M	$-7.77M	$-7.82M	$-8.25M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-11.86M	$-17.69M	$-15.40M	$-23.42M	$-26.13M	$-7.31M	$-6.30M	$-6.77M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-0.22	$-0.34	$-0.30	$-0.48	$-0.54	$-0.11	$-0.09	$-0.12
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Tiziana Life Sciences Ltd

Insider Trading

Discover more